Synopsis
Reduce kidney and cardiovascular events through cause-specific treatment, albuminuria and blood-pressure control, layered protective medicines, and avoidance of preventable injury.
- Treat the cause as well as the risk markers: obstruction, glomerular inflammation, reflux, diabetes and inherited disease cannot be replaced by a generic CKD prescription bundle.
- Blood-pressure control and reduction of albuminuria are central; NICE uses a lower clinic target when ACR is 70 mg/mmol or more, with frailty, falls and home readings shaping individualisation.
- Offer an ACE inhibitor or angiotensin-receptor blocker for eligible albuminuric CKD and titrate to the highest licensed tolerated dose; never combine the two classes solely for proteinuria.
- Check creatinine/eGFR and potassium before renin–angiotensin-system blockade and within 1–2 weeks after starting or increasing it; investigate a large decline rather than assuming every early change is acceptable.
- SGLT2 inhibitors protect kidneys and reduce heart-failure events in eligible CKD with or without diabetes even when their glucose-lowering effect is small; follow current NICE, licence and local criteria.
- A modest early eGFR dip after SGLT2 initiation can be haemodynamic and expected, but hypovolaemia, ketoacidosis, infection and a continuing steep fall need active assessment.
- Finerenone is an add-on option for eligible stage 3–4 albuminuric CKD associated with type 2 diabetes after optimised standard care; potassium monitoring is essential.
- Offer atorvastatin 20 mg for cardiovascular prevention in CKD under NICE lipid guidance, increasing only when appropriate and checking interactions and renal-stage restrictions.
- Smoking cessation, exercise, weight support, salt moderation, vaccination and diabetes care matter, while routine low-protein restriction or indiscriminate potassium avoidance can worsen nutrition.
- Prevent recurrent injury by reviewing NSAIDs, dehydration plans, iodinated contrast context, urinary obstruction and medicines requiring renal dose adjustment at every transition of care.
Key red flags
Severe hyperkalaemia or ECG change after RAS blockade or finerenone requires the acute UKKA pathway; do not wait for a routine repeat sample.
Hypotension, oliguria or a large sustained creatinine rise after treatment initiation may indicate hypovolaemia, renal-artery disease, obstruction, sepsis or NSAID interaction and needs urgent review.
Nausea, abdominal pain, tachypnoea or ketonaemia in an SGLT2-treated patient can be ketoacidosis despite only modest glucose elevation; stop the medicine and use the emergency diabetes pathway.
Rapid eGFR loss with haematuria, systemic inflammation or nephrotic syndrome suggests active renal disease requiring urgent nephrology input rather than routine risk-factor intensification.
Pregnancy or pregnancy planning requires prompt review of ACE inhibitors, ARBs, SGLT2 inhibitors and finerenone because usual CKD protective regimens may be fetotoxic or unsupported.
Investigation priorities
Guide antihypertensive intensity and identify white-coat, masked or postural patterns.
Management branches
Stable CKD carries albuminuric, diabetic, heart-failure or cardiovascular risk suitable for disease modification.
- Confirm cause, G and A stage, blood pressure, volume, potassium, diabetes status, cardiovascular disease, pregnancy potential and current medicines.
- Optimise a single ACE inhibitor or ARB when indicated, checking renal function and potassium after each meaningful dose change.
- Add a licensed SGLT2 inhibitor when current NICE and UKKA eligibility is met, with genital-infection, volume and ketoacidosis counselling.
- For eligible albuminuric type 2 diabetic CKD, consider finerenone after standard care and add lipid, smoking, activity and weight measures without destabilising nutrition.